COVID-19 vaccination and cerebral small vessel disease progression—A prospective cohort study

COVID-19 vaccination and cerebral small vessel disease progression—A prospective cohort study

Objectives: The association between SARS-CoV-2 spike protein and cerebrovascular diseases raised a concern of cerebrovascular safety of COVID-19 vaccines. We aimed to determine the risk of radiologic cerebral small vessel disease (cSVD) progression with BNT162b2 and CoronaVac. Methods: In this commu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yiu Ming Bonaventure Ip, Sangqi Pang, Alan Yao, Lucas Lau, Anki Miu, Katarina Chiu, Ho Ko, Andrew Kwok, Helen Y Chan, Sharon Lee, Howard Chan, Trista Hung, Bonnie Lam, Vincent Hui, Haipeng Li, Lin Shi, Jill Abrigo, Xinyi Leng, Yannie Soo, Sze Ho Ma, Vincent CT Mok, Hugh S Markus, Chris Mok, David SC Hui, Thomas W Leung
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	International Journal of Infectious Diseases
Subjects:	COVID-19 BNT162b2 CoronaVac MRI Cerebrovascular disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971224003990
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
by: Masliyana Husin, et al.
Published: (2025-01-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil
by: Fatima de Cássia Evangelista de Oliveira, et al.
Published: (2025-04-01)

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting
by: Aini Syahida Mat Yassim, et al.
Published: (2025-07-01)

Real-life evaluation of incidence and clinical outcomes of COVID-19 among healthcare workers during pre-vaccination and post-vaccination periods: A cross-sectional impact study
by: Yusuf Emre Ozdemir, et al.
Published: (2023-03-01)

Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong
by: Jialiang Jiang, et al.
Published: (2025-12-01)

Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality
by: Jialiang Jiang, et al.
Published: (2025-02-01)

Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster
by: Shayane Martins Rodrigues Gomes, et al.
Published: (2025-05-01)

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants
by: Yuqing Li, et al.
Published: (2025-12-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort
by: Liguo Zhu, et al.
Published: (2023-12-01)

Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine
by: Renato Kaylan Alves de Oliveira França, et al.
Published: (2025-04-01)

The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac –inactivated COVID-19 vaccines
by: Mine Durusu Tanriover, et al.
Published: (2024-12-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up
by: Camila Amormino Corsini, et al.
Published: (2025-07-01)

Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the Omicron-predominant epidemic wave in the Philippines: a test-negative case–control study
by: Kristal An Agrupis, et al.
Published: (2025-12-01)

Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines
by: Karnsinee Thanborisutkul, et al.
Published: (2025-03-01)

Comparative analysis of humoral immunity kinetics following three COVID-19 vaccines in a multi-ethnic cohort of medical students and healthcare professionals across Malaysia
by: Ashwathy Varadarajan Thundakattil, et al.
Published: (2025-07-01)

Altered expression of miRNA profile in peripheral blood mononuclear cells following the third dose of inactivated COVID-19 vaccine
by: Guanguan Qiu, et al.
Published: (2025-01-01)

Side effects of the Pfizer BioNTech vaccine in health workers of a hospital in the southeast of Mexico
by: Jesús Arturo Ruiz-Quiñones, et al.
Published: (2022-09-01)

Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report
by: Harukazu Hirano, et al.
Published: (2024-12-01)

Löfgren’s Syndrome Following BNT162b2 mRNA COVID-19 Vaccination and Subsequent Plaque-type Cutaneous Sarcoidosis after its Resolution
by: Masahiro Oka, et al.
Published: (2025-06-01)

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
by: Joel M. Neutel, et al.
Published: (2025-02-01)

Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
by: Ho Yu Ng, et al.
Published: (2025-02-01)

COVID-19 vaccination-related attendance at a pediatric emergency department in Singapore among 12- to 18-year old adolescents
by: Nicholas Beng Hui Ng, et al.
Published: (2022-11-01)

A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”
by: Timothy E. Albertson, et al.
Published: (2025-04-01)

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant
by: Valentin Letailleur, et al.
Published: (2024-12-01)

Pre-Vaccination Immune Profiles and Responsiveness to Innate Stimuli Predict Reactogenicity and Antibody Magnitude Following mRNA Vaccination
by: Amanda E. Zelkoski, et al.
Published: (2025-07-01)

COVID-19 Vaccination and Acute Anterior Uveitis—A Case Control Study
by: Asaf Shemer, et al.
Published: (2025-02-01)

Letter to the Editor Regarding "Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination" by Albertson et al. 2024
by: Ivan Pourmir, et al.
Published: (2025-04-01)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution
by: Andreina Baj, et al.
Published: (2021-01-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Comparative study of neutralizing antibodies titers in response to different types of COVID-19 vaccines among a group of egyptian healthcare workers
by: Sara Maher, et al.
Published: (2024-11-01)

Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar
by: Remy Thomas, et al.
Published: (2025-03-01)

Breakthrough Infection After a Primary Series of COVID-19 Vaccination Induces Stronger Humoral Immunity and Equivalent Cellular Immunity to the Spike Protein Compared with Booster Shots
by: Yoshifumi Uwamino, et al.
Published: (2025-07-01)

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
by: Abbass Darwich, et al.
Published: (2022-04-01)

Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review
by: Eleonora Francesca Pattonieri, et al.
Published: (2025-02-01)

SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
by: Weiyi Tang, et al.
Published: (2025-03-01)